Drug Approval | May 26, 2022
Eugia Pharma receives USFDA approval for Pemetrexed
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Investment in technology and people and a meaningful industry-academia partnership can fuel the growth of the Indian biopharma sector
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
ICICI Direct gives a preview on the earnings narrative for Q3FY22
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The drug will be marketed under the brand name Molnaflu
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Subscribe To Our Newsletter & Stay Updated
